Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML.

Mouse models of chronic myeloid malignancies suggest that targeting mature cells of the malignant clone disrupts feedback loops that promote disease expansion. Here, we show that, in chronic myelomonocytic leukemia (CMML), monocytes that accumulate in the peripheral blood show a decreased propensity to die by apoptosis. BH3 profiling demonstrates their addiction to MCL1 (myeloid cell leukemia-1), which can be targeted with the small molecule inhibitor S63845. RNA sequencing and DNA methylation pattern analysis both point also to the implication of the MAPK (mitogen-activated protein kinase) pathway in the resistance of CMML monocytes to death and reveal an autocrine pathway in which the secreted cytokine CYTL1 (Cytokine-like protein 1) promotes ERK (extracellular signal-regulated kinase) activation through CCR2 (C-C chemokine receptor type 2). Combined MAPK and MCL1 inhibition restores apoptosis of CMML patient monocytes and reduces the expansion of patient-derived xenografts in mice. These results designate the combined inhibition of MCL1 and MAPK as a promising approach to slow down CMML progression by inducing leukemic monocyte apoptosis.


View the full article @ Blood


Get PDF with LibKey
Authors: Margaux Sevin, Franck Debeurme, Lucie Laplane, Severine Badel, Margot Morabito, Hannah L Newman, Miguel Torres-Martin, Qin Yang, Bouchra Badaoui, Orianne Wagner-Ballon, Véronique Saada, Dorothée Selimoglu-Buet, Laurence Kraus-Berthier, Sébastien Banquet, Alix Derreal, Pierre Fenaux, Raphaël A Itzykson, Thorsten Braun, Gabriel Etienne, Celine Berthon, Sylvain Thepot, Oliver Kepp, Guido Kroemer, Eric Padron, Maria Eugenia Figueroa, Nathalie M Droin, Eric Solary